Cancer is one of the leading causes of death in industrialized countries. Major breakthroughs in drug discovery for oncology have been hampered by the high costs and the high attrition rate. Classical human cancer models used are cancer cell lines (2D) and in vivo animal models. Although these Oncology models have proven to be useful in the past their utility towards the clinic has vast room for improvement.
InnoSer has started exploring the field of tissue-derived organoids that are obtained during surgery or biopsy comprising of human tumor tissue that are termed Patient Derived Organoid (PDO). Long-term organoids (PDXO) exhibit dysplasia and invasiveness, phenotypically and genetically resembling the original patient-derived tumor. Recently InnoSer has teamed up with leading edge research groups from both academia and industrial partners which has led to a collaborative project to establish PDXO models from primary colon, esophagus, pancreas, stomach, liver, endometrium, prostate and breast tumors.
Subsequently, InnoSer will validate the PDXO model using in vivo animal models to develop a fast and reliable screening model in the drug discovery and preclinical drug development chain.